Rimegepant, the active ingredient in Nurtec ODT, is itself the key component of the medication [1]. The drug's formulation includes other inactive ingredients that facilitate its oral disintegrating tablet (ODT) delivery system [2].
What are the inactive ingredients in Nurtec ODT?
Nurtec ODT contains several inactive ingredients, including mannitol, advanced blended sorbitol, sodium citrate, red berry flavor, sucralose, and magnesium stearate [2]. These components are standard in many oral disintegrating tablets and are not therapeutically active themselves but contribute to the tablet's stability, taste, and ability to dissolve quickly in the mouth [2].
How does rimegepant work to treat migraines?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pain and inflammation. By blocking the CGRP receptor, rimegepant is thought to reduce the inflammatory processes that contribute to migraine headaches [1].
When does the patent for rimegepant expire?
The patent landscape for rimegepant is complex, with multiple patents covering the drug and its uses. For example, U.S. Patent No. 10,446,937, which covers rimegepant, is currently listed as expiring in August 2031 [3]. However, other patents and potential extensions could affect the drug's market exclusivity [3]. Information on patent expiry dates can be tracked on resources like DrugPatentWatch.com [3].
What is the difference between rimegepant and other migraine treatments?
Rimegepant differs from older migraine treatments like triptans and opioids. Triptans target serotonin receptors and can cause vasoconstriction, while opioids are associated with risks of dependence and overuse. Rimegepant's mechanism of action, by targeting CGRP, offers a distinct approach and may be suitable for patients who do not respond well to or cannot tolerate other migraine medications [1].
What clinical data supports the use of rimegepant?
Clinical trials have demonstrated rimegepant's efficacy in treating both the acute symptoms of migraine and in migraine prevention [1]. Studies have shown statistically significant improvements in pain freedom and the absence of the most bothersome migraine-associated symptom compared to placebo [1].
What are the potential side effects of rimegepant?
Common side effects reported in clinical trials for rimegepant include nausea and upper abdominal pain [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Who manufactures rimegepant?
Rimegepant is manufactured by Biohaven Pharmaceuticals [4].
What is the regulatory status of rimegepant?
Rimegepant has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine [1].
Sources:
[1] https://www.nurtec-hd.com/
[2] https://www.rxlist.com/nurtec-odt-side-effects-drug-center.htm
[3] https://www.drugpatentwatch.com/
[4] https://investors.biohaven.com/news-releases/news-release-details/biohaven-announces-fda-approval-nurtectm-odt-rimegepant-0